With a fast-moving pandemic, no one is safe, unless everyone is safe

The vaccines pillar of the <u>ACT-Accelerator</u>, convened by <u>CEPI GAVI</u> and <u>WHO</u>, is speeding up the search for an effective vaccine for all countries. At the same time, it is supporting the building of manufacturing capabilities, and buying supply, ahead of time so that 2 billion doses can be fairly distributed by the end of 2021.

Led by CEPI GAVI and WHO.

COVAX explained


COVID-19 vaccine country readiness and delivery

The country readiness and delivery FAQs

The country readiness and delivery workstream

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and





equitable access for every country in the world.

Why we need COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US\$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

What COVAX offers

- Doses for at least 20% of countries' populations
- Diverse and actively managed portfolio of vaccines
- Vaccines delivered as soon as they are available
- End the acute phase of the pandemic
- Rebuild economies



News

18 December 2020_| Call for experts

COVAX Independent Allocation of Vaccines Group

13 January 2021_| Departmental news

Early childhood development in conflict-affected countries is key to life-long health, wel...

9 December 2020 I CEPI news

CEPI and SK bioscience extend collaboration to develop 'next

generation' COVID-19 vaccine

24 November 2020 | GAVI news

Gavi statement on AstraZeneca/Oxford interim efficacy data

Resources

 $\underline{\text{All}} \rightarrow$



9 November 2020

COVAX: The vaccines pillar of the access to COVID-19 tools (ACT) Accelerator

Download

Read More



15 September 2020

COVAX Facility Explainer

Download

Read More

9 September 2020

Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility

Download

Read More



6 August 2020

COVAX, the ACT-Accelerator vaccines pillar

Download

Read More

Other resources

 $All \rightarrow$

<u>COVAX Self-financing Participants – Legal Agreements and Explanatory Note</u>

COVAX - List of participating economies

COVAX AMC donors table

Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility

<u>Briefing Note: Indemnification & Compensation – COVAX AMC participants</u>

13.01.2021, 09:25

COVAX Facility Explainer
COVAX - CSO Application Guidelines
COVAX Independent Product Group Call for Nominations
Gavi Covax AMC: an investment opportunity
<u>Dialogue with civil society</u>
Responsible media reporting on COVID-19 Vaccines
Gavi Advance Market Commitment for COVID-19 vaccines (Gavi Covax AMC): An investment opportunity
COVAX Independent Product Group Call for Nominations
What is the COVAX pillar, why do we need it and how will it work?
The fastest way out of the pandemic
COVAX: The vaccines pillar of the access to COVID-19 tools (ACT) Accelerator

Related topics

Vaccines and immunization

Coronavirus

Videos

 $\underline{\text{All}} \rightarrow$

21 December 2020

<u>Getting vaccines, medicines and tests ready for emergency use</u>

<u>10 December 2020</u>

Science in 5: Episode #16 - How vaccines work

Media contact

Diane Abad-Vergara

Communications Officer
Telephone: +41 79 200 5878
Email: abadvergarad@who.int

More

COVID-19 vaccines

How do vaccines work?

The ACT-Accelerator

Coronavirus disease (COVID-19) pandemic